

Performance in Initiating and Delivering (PID) Clinical Research
UCLH Performance in Approving and Recruiting to Research
October 2018

Since July 2012, providers of NHS services have been providing data on performance in initiating and delivering clinical research. Data for studies which have received NHS approval (known as Decision to Deliver) in the previous 12 months is submitted quarterly to the National Institute for Health Research (NIHR). Below, a summary of performance submitted by UCLH in Quarter 2 (2018/19) for studies where UCLH was selected as a site over the past year.

Providers are asked to publish details of the length of time taken to approve clinical trials from the point from Date Site Selected to recruitment of the first participant. This period is known as the initiation stage and the NIHR has assigned a benchmark target of 70 days.

Providers also submit information on those Commercially Sponsored Trials, which have closed to recruitment in the year and whether the trial has achieved its anticipated total recruitment target. The period between recruitment of the first participant and reaching the total recruitment target is known as the delivery stage. Each quarter, UCLH will update this information with the most recent studies. The data is correct as of end of September 2018.

For Further information on PID reporting, please visit the NIHR pages at:

<http://www.nihr.ac.uk/policy-and-standards/Performance-in-initiating-and-delivering-research.htm>

Initiating Clinical Research – HRA Approval

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
125631	16/EE/0324	203951	HRA Approval	Prophylactic and Pre-emptive DLI for myeloid malignancies (PRO-DLI)	No		12/09/2017	09/03/2018	08/09/2016	17/05/2018	05/06/2018		06/06/2018	Neither
125632	17/EE/0177	220722	HRA Approval	BOSTON: Open-label Study of SVD versus VD in patients with RRMM	Yes	03/10/2018	16/01/2018	29/03/2018	24/07/2017	30/03/2018	09/07/2018		09/07/2018	Neither
125633	17/WA/0420	235469	HRA Approval	IRL790C003 Phase IIA Parkinson's Dykinesia Study	Yes	18/09/2018	13/04/2017	12/06/2018	17/01/2018	25/05/2018	22/06/2018		22/06/2018	Sponsor

12563 4	16/EM/03 22	202096	HRA Approval	Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)	No		24/11/20 17	21/05/20 18	18/08/20 17	02/07/20 18	17/07/20 18		17/07/20 18	Neither
12563 5	17/WS/02 56	233393	HRA Approval	BLU-667 in Lung Cancer, Thyroid Cancer and Other Solid Tumours	Yes	02/08/20 18	01/11/20 17	30/11/20 17	13/03/20 18	24/04/20 18	27/04/20 18		30/04/20 18	Sponsor
12563 6	17/LO/192 0	235022	HRA Approval	Phase 3 Open-label with BIVV009 in Subjects with CAgD	Yes	21/08/20 18	31/10/20 17	08/12/20 17	27/02/20 18	26/06/20 18	26/07/20 18		26/07/20 18	Sponsor
12563 7	17/SC/022 9	225742	HRA Approval	OM01.01.02	Yes	27/03/20 18	01/11/20 17	07/11/20 17	08/06/20 17	09/02/20 18	23/02/20 18		23/02/20 18	Sponsor
12563 8	17/LO/192 1	236323	HRA Approval	Phase 3 with BIVV009/Placebo in Subjects with CAgD	No		31/10/20 17	08/12/20 17	27/02/20 18	03/07/20 18	26/07/20 18		26/07/20 18	Sponsor
12563 9	17/NS/006 5	219548	HRA Approval	Physical activity and stoma study	Yes	29/05/20 18	12/07/20 17	31/10/20 17	02/10/20 17	25/10/20 17	28/11/20 17			Neither

125640	17/LO/1861	210692	HRA Approval	NEOlung	Yes	30/04/2018	15/08/2016	06/12/2017	04/01/2018	12/01/2018	22/01/2018			Sponsor
125641	17/LO/1808	231108	HRA Approval	ICON9	No		04/07/2017	20/06/2018	18/12/2017	19/09/2018	13/09/2018		24/09/2018	Sponsor
125642	17/LO/1929	233885	HRA Approval	Keynote 669	No		07/11/2017	18/01/2018	19/02/2018	14/02/2018	21/02/2018		08/03/2018	Neither
125643	17/SS/0082	222441	HRA Approval	SoSTART	No		10/09/2016	21/02/2018	05/10/2017	24/05/2018	31/05/2018		04/06/2018	Neither
125644	17/NS/0018	223787	HRA Approval	The Future Study	Yes	04/09/2018	13/10/2017	17/11/2017	01/10/2017	16/01/2018	06/03/2018		06/03/2018	Neither
125645	16/LO/1637	211258	HRA Approval	GCT1021-01	Yes	20/06/2018	25/10/2017	03/04/2018	08/11/2016	22/05/2018	25/05/2018		25/05/2018	Sponsor
125646	18/LO/0116	239646	HRA Approval	Prexasertib in Recurrent Ovarian Cancer (JTJN)	Yes	17/04/2018	02/01/2018	24/01/2018	26/03/2018	08/03/2018	06/04/2018		10/04/2018	Sponsor
125647	17/EE/0303	228718	HRA Approval	Effect of MIN-102 in Male Patients with Adrenomyeloneuropathy	Yes	19/04/2018	23/06/2017	03/10/2017	14/09/2017	30/01/2018	06/04/2018		06/04/2018	Neither
125648	17/LO/1656	229212	HRA Approval	IMspire 170	Yes	22/05/2018	13/07/2017	09/10/2017	14/11/2017	07/12/2017	15/01/2018		17/01/2018	Neither
125649	17/EM/0077	206480	HRA Approval	LACI-2	Yes	17/09/2018	24/08/2017	26/04/2018	24/07/2017	01/06/2018	12/06/2018		28/06/2018	Both
125650	17/LO/0948	222446	HRA Approval	FABULAS	Yes	22/02/2018	02/11/2017	13/11/2017	01/11/2017	19/12/2017	28/12/2017		28/12/2017	Sponsor
125651	17/YH/0123	203556	HRA Approval	SeluDex	No		01/02/2018	28/03/2018	12/12/2017	11/04/2018	02/08/2018		02/08/2018	NHS Provider

12565 2	17/SW/02 47	231651	HRA Approval	NP39403-RO6870810 as monotherapy and in combination in advanced MM	Yes	19/03/20 18	21/09/20 17	20/10/20 17	05/12/20 17	16/01/20 18	23/01/20 18		25/01/20 18	Sponsor
12565 3	18/LO/022 6	231912	HRA Approval	B7661001 - PF-06647020 in patients with Advanced Solid Tumor	No		21/09/20 17	31/01/20 18						Sponsor
12565 4	17/NS/007 7	218279	HRA Approval	BLAST OSA study version 01A multicenter, prospective, open- label, non-randomised	No		09/08/20 17	01/11/20 17	03/10/20 17	15/11/20 17	07/12/20 17		07/12/20 17	Sponsor

12565 5	16/SC/020 1	202977	HRA Approval	A Study of OXB-102, a Gene Therapy, for Parkinsons Disease	Yes	01/10/20 18	07/09/20 16	12/02/20 18		19/07/20 18	25/07/20 18		01/10/20 18	Sponsor
12565 6	18/SC/002 8	235714	HRA Approval	CC-92480 with Dexamethasone in Relapsed & Refractory Multiple Myeloma	Yes	19/09/20 18	17/01/20 18	29/01/20 18		31/05/20 18	26/07/20 18		26/07/20 18	Neither
12565 7	17/SC/060 5	234167	HRA Approval	Phase 1/2 dose-escalation study of CTX-SPL9111 in cancer patients	No		25/10/20 17	07/11/20 17	30/01/20 18		13/06/20 18		13/06/20 18	Neither
12565 8	17/LO/167 8	211950	HRA Approval	Lateral Flow Assay and Reader for Malaria Detection version 1.0	No		12/11/20 17	29/05/20 18	08/11/20 17		04/06/20 18		04/06/20 18	Neither

125659	17/EE/0474	229785	HRA Approval	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	No		24/11/2017	21/05/2018	05/01/2018	22/05/2018	30/05/2018		30/05/2018	Neither
125660	17/LO/1896	233209	HRA Approval	A Phase 1 study of ADCT-502 in patients with advanced solid tumours	No		22/09/2017	06/11/2017	24/10/2017	20/03/2018	05/04/2018		05/04/2018	Sponsor
125661	17/YH/0120	208838	HRA Approval	DISC - Dupuytren's Interventions Surgery vs Collagenase	No		17/07/2017	16/05/2018	25/05/2017	05/06/2018	12/06/2018		12/06/2018	Neither
125662	15/NW/0376	115570	HRA Approval	ReBeL Phase II (A HOVON 110FL/GLSG/NCRI study)	No		04/04/2017	05/04/2018			27/07/2018			Both

12566 3	17/LO/190 0	235038	HRA Approval	Phase 1/2 study of INCB001158 in advanced or metastatic solid tumors	Yes	01/03/20 18	23/10/20 17	20/12/20 17		14/02/20 18	20/02/20 18		21/02/20 18	Sponsor
12566 4	17/LO/203 2	235018	HRA Approval	Phase 1/2 Study to Evaluate CORT125281 with Enzalutamide in Patients with Prostate Cancer	No		27/02/20 18	02/03/20 18	19/02/20 18					NHS Provider
12566 5	18/LO/044 8	241283	HRA Approval	CALDOSE - 1	No		19/02/20 18	01/05/20 18	03/05/20 18		21/08/20 18			Sponsor
12566 6	17/SC/036 9	218189	HRA Approval	NEPTUNES	Yes	20/06/20 18	24/05/20 17	17/10/20 17	09/10/20 17	27/10/20 17	30/11/20 17		30/11/20 17	Sponsor
12566 7	17/EE/037 0	233951	HRA Approval	TNT009-01: SAFETY, TOLERABILITY AND ACTIVITY OF TNT009	No		23/08/20 15	17/11/20 17						Sponsor
12566 8	17/SC/061 5	233555	HRA Approval	VIOLETTE	No		30/01/20 18	09/07/20 18			03/08/20 18		03/08/20 18	NHS Provider

125669	17/YH/0289	231276	HRA Approval	A phase 1/2 study with Acalabrutinib and AZD6738 in high risk CLL	Yes	11/09/2018	02/01/2018	22/01/2018	18/10/2017	24/05/2018	18/06/2018		18/06/2018	Neither
125670	16/LO/1355	168344	HRA Approval	InPACT	No		31/10/2017	20/06/2018						Neither
125672	18/LO/0021	236581	HRA Approval	EACH	Yes	19/09/2018	27/03/2018	11/07/2018	26/03/2018		16/07/2018			
125673	18/LO/0144	239494	HRA Approval	Intra-oral treatment of OLP with Rivelin®-CLO patches	Yes	18/09/2018	04/12/2017	10/07/2018	17/05/2018		09/08/2018			
125674	18/LO/0862	241382	HRA Approval	RCT: CO THA vs Mako THA	No		03/05/2018	23/07/2018						
125675	18/LO/1141	241087	HRA Approval	Minifast - Obs	No		18/01/2018	25/07/2018	24/07/2018		09/08/2018		09/08/2018	
125676	18/LO/0227	228539	HRA Approval	A feasibility study of ACT for people with MND (Phase 1) v1	Yes	14/09/2018	23/08/2017	11/07/2018			27/07/2018			

125677	18/LO/0793	241404	HRA Approval	RCT: Mako FA TKA vs Mako MA TKA	No		18/06/2018	31/07/2018						
125678	17/SC/0536	216069	HRA Approval	COPELIA	No		19/10/2017	31/07/2018			06/09/2018		06/09/2018	
125679	18/LO/0696	245087	HRA Approval	Phase 2/3 Study of Arimoclomol in IBM	Yes	31/08/2018	12/12/2016	02/07/2018			03/08/2018		03/08/2018	
125680	18/LO/0951	241359	HRA Approval	AB-PSP-001	No		10/04/2018	06/08/2018	19/07/2018		26/09/2018		26/09/2018	
125681	18/EM/0079	230431	HRA Approval	Vaccination for immune recovery following sepsis: The VACIRISS Trial	No		12/04/2018	08/08/2018	16/04/2018					
125682	18/SC/0412	250170	HRA Approval	Pembro/Placebo+Trastuzumab+ Chemo in HER2+ Metastatic Gastric/GEJ	No		14/05/2018	08/08/2018						
125683	18/LO/0789	238844	HRA Approval	FLICC II	No		09/06/2017	14/08/2018						
125684	18/LO/0165	224726	HRA Approval	POLEM	No		12/06/2017	16/08/2018						

125685	17/WS/0081	225638	HRA Approval	QUIDS 2	Yes	11/07/2018	09/05/2018	29/05/2018	15/08/2017	13/06/2018	22/06/2018		22/06/2018	
125686	18/LO/1148	240856	HRA Approval	THRIVEN90	No		31/07/2018	22/08/2018	31/07/2018		19/09/2018		19/09/2018	
125687	18/EE/0197	246434	HRA Approval	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	No		11/06/2018	22/08/2018	10/08/2018					
125688	18/EM/0085	208868	HRA Approval	HOVON 127 BL	No		27/07/2018	22/08/2018						
125689	18/EM/0119	244650	HRA Approval	Chemotherapy+/- MK-3475 in TKI-resistant EGFR-mutated Tumors in NSCLC	No		13/02/2018	30/08/2018			03/09/2018			
125690	18/EM/0119	244650	HRA Approval	Chemotherapy+/- MK-3475 in TKI-resistant EGFR-mutated Tumors in NSCLC			13/02/2018	30/08/2018			03/09/2018			
125691	18/SS/0059	224730	HRA Approval	PROHIBIT-ICH	No		15/12/2017	12/09/2018						
125692	17/NW/0634	209375	HRA Approval	COMICE	No		05/09/2016	20/09/2018						

125693	18/LO/0030	225990	HRA Approval	BARI-OPTIMISE Version 1	No		28/09/2017	21/09/2018			25/09/2018			
125694	18/LO/0995	244737	HRA Approval	Lenvatinib plus Pembrolizumab to Treat Advanced Endometrial Cancer	No		28/12/2017	21/09/2018	20/09/2018					
125695	17/LO/0727	217211	HRA Approval	Phase 2/3 study in neonates with repeated EEG seizures	No		21/03/2017	24/09/2018	21/05/2018					
125696	18/LO/0396	238968	HRA Approval	NP40126 - A Phase 1B Study Evaluating RO7082859 in Lymphoma	No		15/03/2018	17/04/2018	16/05/2018		02/08/2018			Neither
125697	17/LO/1273	216265	HRA Approval	CheckMate 648	Yes	19/06/2018	22/05/2017	10/01/2018	30/08/2017	10/01/2018	18/01/2018		18/01/2018	Neither
125698	17/NW/0512	221775	HRA Approval	PETReA	No		06/10/2017	18/04/2018						NHS Provider
125699	18/EM/0112	236871	HRA Approval	ALL-RIC	No		18/04/2018	19/07/2018						NHS Provider
125700	17/NI/0203	187583	HRA Approval	Short pulse width DBS	Yes	02/05/2018	08/01/2018	15/03/2018		22/03/2018	23/03/2018		23/03/2018	

12570 1	17/LO/002 4	212247	HRA Approval	I3Y-MC-JPCJ	Yes	31/10/20 17	30/08/20 16	03/10/20 17	05/04/20 17	12/09/20 17	03/10/20 17		10/10/20 17	
12570 2	17/LO/184 6	227211	HRA Approval	Digital Interventions in Neuro- Rehabilitation (DINR)	Yes	08/03/20 18	18/12/20 17	17/01/20 18			26/01/20 18		26/01/20 18	
12570 3	17/LO/150 9	232288	HRA Approval	MS-STAT2	Yes	29/03/20 18	01/09/20 17	18/01/20 18	19/01/20 18	01/02/20 18	02/02/20 18		02/02/20 18	
12570 4	18/NI/008 4	239210	HRA Approval	Phase 3 trial to evaluate subcutaneous elamipretide injections for PMM	No		14/02/20 18	03/07/20 18						Sponsor
12570 5	17/EE/004 0	222216	HRA Approval	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	No		11/09/20 17	02/02/20 18	02/03/20 17		15/02/20 18		15/02/20 18	Neither
12570 6	17/NE/006 1	215780	HRA Approval	CONVINCE - Protocol Version 2.1 29th November 2016	Yes	20/08/20 18	18/08/20 17	05/04/20 18	25/07/20 17	15/05/20 18	15/05/20 18		15/05/20 18	Neither

125707	17/LO/1433	226791	HRA Approval	WATS CDX 810	Yes	27/02/2018	29/04/2017	01/02/2018	31/01/2018	21/02/2018	23/02/2018		23/02/2018	
125708	18/LO/0047	235607	HRA Approval	ARTISAN-SNM 105-0050	Yes	11/04/2018	23/01/2018	08/02/2018	22/02/2018	22/02/2018	23/02/2018		23/02/2018	
125709	17/LO/1972	231646	HRA Approval	DSA vs Posterior Approach THA	Yes	07/07/2018	02/02/2018	21/03/2018	02/01/2018		29/03/2018		03/04/2018	Neither
125710	17/LO/0871	215297	HRA Approval	MePFAC	Yes	29/06/2018	03/08/2017	23/05/2018	05/04/2018	23/05/2018	24/05/2018		24/05/2018	
125711	18/NW/0172	242180	HRA Approval	STEP 1 - Semaglutide Treatment Effect in People with obesity	Yes	26/06/2018	15/12/2017	01/06/2018	17/05/2018	01/06/2018	15/06/2018		15/06/2018	
125712	18/LO/0370	241124	HRA Approval	68Ga-THP-PSMA PET/CT imaging in primary and recurring prostate cancer	Yes	25/06/2018	08/01/2018	24/05/2018	17/05/2018	13/06/2018	13/06/2018		15/06/2018	

12571 3	17/EE/036 8	213669	HRA Approval	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)	Yes	19/04/20 18	01/09/20 17	21/02/20 18	10/11/20 17	15/03/20 18	20/03/20 18		20/03/20 18
------------	----------------	--------	-----------------	--	-----	----------------	----------------	----------------	----------------	----------------	----------------	--	----------------

Delivering Clinical Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
31507	16/LO/1810	209789	UTX-TGR-304	Number Agreed	3	3	Date Agreed	30/05/2018	3	12/10/2017	0	Recruitment Finished
31508	10/H1102/44	0	MCRN146 (AC-056C501)	Not Available / Not Agreed			Not Available / Not Agreed			19/10/2017	2	Recruitment Finished
31509	16/LO/1436	205613	Potential Predictors of Disease Progression in aHUS Patients	Number Agreed	10	10	Date Agreed	30/06/2018	6	31/10/2017	6	Recruitment Finished
31510	15/LO/1936	183134	CANC - 4615	Number Agreed	3	3	Date Agreed	31/05/2017	0	13/11/2017	2	Withdrawn By Sponsor
31511	17/EM/0089	222705	BREAKOUT	Number Agreed	10	10	Date Agreed	28/02/2018	1	15/11/2017	1	Withdrawn By Sponsor
31512	16/SS/0134	199690	STRO 4724	Number Agreed	1	1	Not Available / Not Agreed			17/11/2017	1	Withdrawn By Sponsor
31513	16/LO/1960	199019	Dose finding study of Sarilumab in children with sJIA	Number Agreed	1	1	Not Available / Not Agreed			20/11/2017	0	Recruitment Finished

31514	15/LO/1950	184545	A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence II)	Number Agreed	10	10	Date Agreed	01/11/2017	11	30/11/2017	11	Recruitment Finished
31515	17/SC/0033	218114	A phase 3 randomized, open-label, multicenter study comparing isatuximab (SAR650984) in combination with pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory mu	Number Agreed	2	2	Not Available / Not Agreed			01/01/2018	3	Recruitment Finished
31516	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	10	10	Not Available / Not Agreed			12/01/2018	0	Withdrawn By Sponsor
31517	17/LO/0640	204303	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders	Number Agreed	3	3	Date Agreed	31/12/2017	2	31/01/2018	2	Recruitment Finished

			associated with Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)								
31518	16/LO/0574	150998	Phase I/II, First in Human, Dose Escalation Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with Relapsed/Refractory B Cell Malignancies and Expansion Cohorts in Patients with Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma	Number Agreed	6	6	Not Available / Not Agreed		31/01/2018	3	Recruitment Finished
31519	16/NE/0142	202233	A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer	Number Agreed	3	3	Not Available / Not Agreed		01/02/2018	6	Recruitment Finished
31520	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Number Agreed	4	4	Not Available / Not Agreed		05/02/2018	3	Recruitment Finished

31521	17/NW/0228	222219	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma	Number Agreed	2	2	Date Agreed	30/04/2018	5	13/02/2018	5	Recruitment Finished
31522	16/WM/0512	218042	A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ferric Maltol at Three Dosage Levels in Paediatric Subjects aged 10-17 years of age with iron deficiency (with or witho	Number Agreed	9	9	Not Available / Not Agreed			15/03/2018	1	Recruitment Finished
31523	15/LO/0685	148762	A comparison of Glycosade? and Uncooked Cornstarch (UCCS) for the treatment of hepatic glycogen storage diseases (GSD)	Number Agreed	2	2	Date Agreed	01/04/2016	3	31/03/2018	3	Recruitment Finished
31524	17/NE/0201	218005	A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)	Number Agreed	8	8	Not Available / Not Agreed			31/01/2018	10	Recruitment Finished
31525	17/LO/0169	214075	SPI2	Number Agreed	15	15	Date Agreed	30/09/2017	6	11/05/2018	17	Recruitment Finished
31526	16/EM/0252	202691	LemQoL	Number Agreed	6	6	Not Available / Not			14/05/2018	6	Recruitment Finished

							Agreed					
31527	15/SC/0659	189114	DEME 4996	Number Agreed	2	2	Date Agreed	28/04/2017	0	08/06/2018	11	Withdrawn By Sponsor
31528	16/EE/0296	210289	A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome	Number Agreed	4	4	Date Agreed	31/10/2016	0	26/04/2018	4	Recruitment Finished
31529	17/NE/0115	218417	MA39189	Number Agreed	3	3	Date Agreed	30/04/2018	0	01/03/2018	1	Recruitment Finished
31530	16/SC/0035	194232	A Phase III Study of Pembrolizumab vs. Chemotherapy in MSI-H or dMMR S	Number Agreed	18	18	Not Available / Not Agreed			31/03/2018	18	Recruitment Finished
31531	16/NE/0342	213304	ADCT-402-101	Number Agreed	17	17	Date Agreed	28/02/2018	17	04/04/2018	17	Recruitment Finished
31532	14/NW/1092	142160	NCRN - 2674: Autologous EBV-specific T-cells for the treatment of ENKTCL	Number Agreed	2	2	Date Agreed	30/12/2015	0	01/11/2017	5	Withdrawn By Host
31533	17/EM/0208	225066	COSIMO: Cancer associated thrombosis-patient reported outcomes	Not Available / Not Agreed			Not Available / Not Agreed			15/05/2018	18	Recruitment Finished
31534	16/WM/0433	215494	TRAIT	Not Available / Not Agreed			Date Agreed	29/01/2016	0	30/04/2018	32	Recruitment Finished
31535	12/SC/0584	109643	CCRN 1093 (aHUS)	Number Agreed	30	30	Date Agreed	30/06/2017	26	10/01/2018	32	Withdrawn By Sponsor
31536	16/LO/1782	213379	Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer	Number Agreed	3	3	Date Agreed	30/01/2017	0	01/02/2018	5	Withdrawn By Sponsor

31537	17/EE/0128	222308	N/A	Not Available / Not Agreed			Not Available / Not Agreed			21/05/2018	2	Recruitment Finished
31538	15/LO/2098	182147	CRIT 3822	Number Agreed	14	14	Date Agreed	28/12/2015	0	11/12/2017	15	Withdrawn By Sponsor
31539	15/SC/0676	186964	CANC - 3899 Olaratumab plus doxorubicin vs. placebo plus doxorubicin advanced or metastatic STS	Not Available / Not Agreed			Date Agreed	30/06/2017	1	27/05/2018	1	Recruitment Finished
31540	17/LO/1043	226184	ECHO 206: epacadostat in combination with pembrolizumab and azacitadine	Not Available / Not Agreed			Not Available / Not Agreed			14/05/2018	52	Withdrawn By Sponsor
31541	16/NW/0086	198831	CANC - 4775	Number Agreed	2	2	Date Agreed	29/04/2016	0	08/05/2018	0	Withdrawn By Sponsor
31542	16/EE/0463	214371	CompLEEment-1	Number Agreed	10	10	Date Agreed	30/12/2019	0	16/10/2017	10	Recruitment Finished
31543	17/LO/0436	214612	Development of an MCM5 ELISA test for oesophageal cancer	Not Available / Not Agreed			Date Agreed	30/11/2017	0	14/05/2018	0	Recruitment Finished
31544	17/LO/0627	218496	Study of VAL-1221 in Patients with Pompe Disease (VAL-1221-201-16)	Number Agreed	4	4	Date Agreed	31/08/2017	0	14/05/2018	4	Recruitment Finished
31545	15/LO/1906	192701	GAST 5150	Not Available / Not Agreed			Not Available / Not Agreed			30/04/2018	3	Recruitment Finished
31546	16/NE/0353	211988	ARASENS	Number Agreed	4	4	Date Agreed	28/04/2017	0	22/03/2018	7	Recruitment Finished
31547	15/SC/0009	170938	CANC - 4476	Not Available			Date Agreed	30/05/2016	0	20/06/2018	12	Recruitment Finished

				/ Not Agreed								
31548	15/LO/1979	181054	NEUR 4538	Not Available / Not Agreed			Date Agreed	30/12/2016	13	31/03/2018	38	Recruitment Finished
31549	17/LO/0693	226490	Long-term safety of Everolimus in patients with TSC related seizures	Number Agreed	2	2	Date Agreed	27/09/2017	0	23/10/2017	2	Recruitment Finished
31550	17/LO/1502	232726	ISIS-443139-CS2 - Open label extension study	Number Agreed	6	6	Date Agreed	30/05/2018	9	12/03/2018	7	Recruitment Finished
31551	13/EE/0326	137999	SRN066 Revacept in Carotid Artery Stenosis	Not Available / Not Agreed			Date Agreed	30/06/2015	12	14/05/2018	8	Recruitment Finished
32506	16/LO/1222	191705	ATLANTIS Trial (PharmaMar)	Number Agreed	5	5	Date Agreed	31/12/2017	9	30/07/2018	9	Recruitment Finished
32507	17/LO/0064	198058	FORWARD 1	Number Agreed	3	3	Date Agreed	21/06/2018	2	23/04/2018	2	Recruitment Finished
32508	17/SC/0609	235575	Daiichi Sankyo DS8201-A-U201 (DS-8201a)	Number Agreed	1	1	Not Available / Not Agreed			12/09/2018	1	Recruitment Finished
32509	15/SS/0148	181087	221AD301: ENGAGE	Not Available / Not Agreed			Date Agreed	28/12/2018	15	04/05/2018	15	Recruitment Finished
32510	16/LO/1744	211158	KIDES-203	Number Agreed	5	5	Date Agreed	30/06/2017	5	16/02/2018	5	Withdrawn By Sponsor
32511	17/LO/0247	213278	OX40	Number Agreed	15	15	Date Agreed	30/09/2017	10	26/07/2018	10	Withdrawn By Host
32512	15/LO/0710	177905	EMBARK:MDV310013	Number Agreed	6	6	Date Agreed	31/12/2016	0	17/03/2018	0	Withdrawn By Host

32513	16/NW/0628	194200	A phase 1b/2 study of DS-1040b in patients with acute ischaemic stroke	Not Available / Not Agreed			Date Agreed	28/02/2019	1	27/04/2018	1	Withdrawn By Sponsor
-------	------------	--------	--	----------------------------	--	--	-------------	------------	---	------------	---	----------------------